HealthCare Global Enterprises LimitedのEBITDA marginは18.33%です。
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer and fertility. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates four multi-specialty hospitals, including three under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat, as well as one under operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, and pulmonary and critical care. In addition, the company offers medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. As of March 31, 2022, the company operated 22 comprehensive cancer centers, including 1 center in Africa. The company was founded in 1989 and is based in Bengaluru, India.